Friedrich Felix Hoyer

Friedrich Felix Hoyer

Auto-generated profile, based on publicly available information

Friedrich Felix Hoyer

Faculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, Heart Center (S.G., A.H., E.S.P., E.W., C.S., K.S., S.N., H.N., L.M.H., N.A.R., P.S., M.M., H.W., S.B., F.F.H.), University of Cologne, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2025 in Circulation Research
Verified
Journal Article
Open access
SGSimon Geissen
Simon Geissen
AHAlexander Hof
Alexander Hof
EPElvina Santhamma Philip
Elvina Santhamma Philip
EWElena Wagner
Elena Wagner
CSCharlotte Schreiber
Charlotte Schreiber
FHFriedrich Felix Hoyer
Friedrich Felix Hoyer
BACKGROUND: Patients with bacterial infections are at increased risk for subsequent cardiovascular events. Whether infections’ effects on innate immune cells within the cardiovascular system influence subsequent pathologies remains unclear. Here, we explore cardiac myeloid cells’ chronic adaptations to a preceding bacterial insult and implications for subsequent myocardial ischemia. METHODS: We used various flow cytometry protocols to assess cardiac immune cells, peripheral leukocytes, and hematopoietic stem and progenitor cells in bone marrow and spleen. A genetic fate-mapping model was used to determine cardiac macrophages’ origin after bacteremia. Cardiac leukocytes were analyzed using single-cell RNA sequencing. Nanoparticle-mediated RNA interference was used to target macrophages in vivo. RESULTS: Cardiac macrophage numbers increased sharply, and numerical changes alongside subset alterations persisted over time. Fate-mapping pointed toward local origin as the primary macrophage source after infection. Profiling macrophage heterogeneity using single-cell RNA sequencing, we identified two previously unknown subpopulations remaining after resolution of infection. While heightened metabolic activity was one subset’s primary feature, the other displayed excessive chemotactic properties, which amplified cardiac leukocyte recruitment and inflammation after a subsequent ischemic injury. Targeting cardiac macrophages’ surplus inflammatory activity after infection using nanoparticle-enabled, macrophage-directed RNA interference kept disproportionate subsequent ischemic inflammation at bay. CONCLUSIONS: Bacteremia induces long-lasting changes in the cardiovascular system’s innate immune cells’ composition. This may amplify myocardial inflammation after a subsequent ischemic injury.

2 September 2026
Verified
Journal Article
Open access
PDF file
SNSuchitra Narayan
Suchitra Narayan
MGMina Girgis
Mina Girgis
SBStephan Baldus
Stephan Baldus
CWChristina Weisheit
Christina Weisheit
HWHolger Winkels
Holger Winkels
FHFriedrich Felix Hoyer
Friedrich Felix Hoyer
The aorta is increasingly recognized as an immunologically active organ, with studies reporting both resident and recruited myeloid cells throughout its anatomical range. Substantial evidence from experimental and clinical studies suggests that both adaptive and innate immune cells contribute to the pathogenesis of major aortic diseases. This review aims to present the current understanding of myeloid cell biology in the aorta, structured along both anatomical and disease-specific dimensions. We recapitulate the anatomy of the aorta, with an emphasis on the regional immune heterogeneity that underlies segment-specific disease susceptibility. We discuss the role of myeloid cells in prenatal aortic development and their contributions to hematopoietic stem cell emergence within the aorta-gonad-mesonephros region and to cardiac valve morphogenesis, followed by an overview of myeloid populations found in the healthy adult aorta. Subsequent sections address myeloid involvement in congenital aortic disease, calcific aortic valve stenosis, aortic dissection, and aortic aneurysm. Across these pathological states, studies have reported on mechanisms involving myeloid cells. The review concludes with an evaluation of myeloid-targeted therapeutic strategies, discussing lessons from clinical trials and the rationale for emerging inflammasome inhibitors, cytokine blockade, macrophage-targeting approaches, and biomarker studies. In summary, the available evidence suggests that myeloid cells may be involved in aortic pathology across the full anatomical and clinical spectrum, and their convergent inflammatory mechanisms may represent a potential therapeutic opportunity in aortic disease.